OneThree Biotech, a NYC-based biology-driven artificial intelligence platform that optimizes drug discovery and development, closed a $2.5M seed funding round.
The round was co-led by Primary Venture Partners and Meridian Street Capital.
The company intends to use the funds to scale and build out the platform’s backend infrastructure and further validate the technology through partnerships with biotech and pharma.
Founded by Neel S. Madhukar, Ph.D., Olivier Elemento, Ph.D., Coryandar Gilvary, Ph.D., and Bradlay Pryde, OneThree Biotech uses a biology-driven artificial intelligence (AI) platform to optimize pre-clinical drug discovery and development.
The company has proven out their approach through Phase 2 trial results with Oncoceutics. The results of the trial highlighted how their technology can improve the outcome of patients diagnosed with rare brain cancer by identifying treatments that could improve average survival from ~3 months to over a year for some patients.
Beyond Oncoceutics, past and current partners and collaborators for OTB’s technology include Weill Cornell Medicine, Cornell Tech, Nvidia, Fox Chase Cancer Center, Cleveland Clinic, The Rockefeller University, Stanford University, and the Icahn School of Medicine at Mount Sinai.
In addition to the new financing, in an effort to help COVID-19 research, OneThree Biotech is offering free AI-based toxicity screening to any researcher working on developing a new drug to treat COVID-19.